Research News

  • Glioblastoma : new treatment attacks brain tumors from multiple angles
    13 November 2024

    Glioblastoma : new treatment attacks brain tumors from multiple angles

    Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly. Researchers at the University of Basel and University Hospital Basel have now developed an immunotherapy that not only attacks the tumor—it also turns its microenvironment against it.

  • 29 October 2024
    Heart failure mortality declining in Sweden

    A new study from Karolinska Institutet shows that heart failure mortality has decreased in Sweden over the last 20 years. The study has been published in the European Journal of Heart Failure. 

    A national study has shown that heart failure mortality has decreased in Sweden over the last two decades. Despite these improvements, the prognosis for heart failure patients remains worrying – 25 percent of those diagnosed in 2022 died within a year.

  • 29 October 2024
    RSV Vaccines Effective, But More People Need to Get Them
    The evidence is clear; individuals should get vaccinated if they have conditions that place them at risk for severe disease. For older adults and those with chronic conditions, RSV should be considered as serious as the flu, and they should get vaccinated
  • 9 October 2024
    India evolving as antimicrobial stewardship

    Study finds that in contrast to developed countries that kept resistance levels under control, a considerable increase in resistance to various classes of antibiotics occurred in ESKAPE pathogens in India over the 2010-2020 decade. The study is published in the International Journal of Antimicrobial Agents.

  • 8 October 2024
    WHO adds an HPV vaccine for single-dose use
    WHO announced that a fourth WHO-prequalified human papillomavirus vaccine product, Cecolin has been confirmed for use in a single-dose schedule. The decision is made based on new data on the product that fulfilled the criteria set out in the WHO 2022 recommendations for alternative, off-label use of HPV vaccines in single-dose schedules.
  • 30 September 2024
    Scientists discover gene responsible for rare, inherited eye disease
    Scientists at the National Eye Institute and their colleagues have identified a gene responsible for some inherited retinal diseases, which are a group of disorders that damage the eyes light-sensing retina and threatens vision. Though IRDs affect more than 2 million people worldwide, each individual disease is rare, complicating efforts to identify enough people to study and conduct clinical trials to develop treatment.
  • 30 September 2024
    Scientists design new drug to fight malaria
    A team led by scientists at UC Riverside, UC Irvine, and Yale School of Medicine has now designed a new drug against malaria and identified its mechanism of action. The researchers found the drug, called MED6-189, is effective against drug-sensitive and drug-resistant P. falciparum strains in vitro as well as in a humanized mouse model the mice were engineered to have human blood.
  • 23 September 2024
    FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration

    The U.S. Food and Drug Administration approved FluMist for self- or caregiver-administration. FluMist is approved for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age. FluMist is sprayed into the nose and has been used safely and effectively for many years. It was initially approved by the FDA in 2003 for use in individuals 5 through 49 years of age, and in 2007, the FDA approved the use of FluMist to include children 2 through 5 years of age.

  • 23 September 2024
    Sarclisa approved in the US as the first anti-CD38 therapy
    The US Food and Drug Administration has approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone as a first line treatment option for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant
  • 20 September 2024
    Antiviral-Resistant Variants of SARS-CoV-2 Can Emerge in Immunocompromised People
    Researchers isolated SARS-CoV-2 strains, which are drug resistant with mutations to the nsp12 protein that is the target of remdesivir and another variant with mutations to the nsp5 protein, the target of Paxlovid. These mutations help the virus persist in people with compromised immunity despite common antiviral treatments.
Subscribe to Research News